Literature DB >> 24507584

Colorectal cancer, diabetes and survival: epidemiological insights.

M M J Zanders1, P A J Vissers2, H R Haak3, L V van de Poll-Franse2.   

Abstract

Colorectal cancer (CRC) patients with pre-existing diabetes have significantly lower rates of overall survival compared with patients without diabetes. Against this backdrop, the American Diabetes Association and American Cancer Society in 2010 reviewed the scientific literature concerning diabetes and cancer. One of the key issues identified for further investigation was the need for a better understanding of whether diabetes influences cancer prognosis above and beyond the prognosis conferred by each disease state independently. Whether the worsened survival of CRC patients with diabetes could be explained by less favourable patient-, tumour- and treatment-related characteristics has also been evaluated in numerous recent studies. However, as most studies did not account for all the various potential confounders, such as cancer stage, comorbidities and body mass index (BMI) in their analyses, the current evidence for the association between diabetes and survival in CRC patients remains inconclusive. Nevertheless, based on multiple examples in the literature, the present review demonstrates that diabetes affects the presentation of CRC as well as its treatment and outcome, which may then result in lower overall rates of survival in patients with, compared to those without, diabetes.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Diabetes; Overall survival; Review

Mesh:

Substances:

Year:  2014        PMID: 24507584     DOI: 10.1016/j.diabet.2013.12.007

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  7 in total

1.  AGR2 silencing contributes to metformin-dependent sensitization of colorectal cancer cells to chemotherapy.

Authors:  Andrea Martisova; Lucia Sommerova; Katarina Kuricova; Jan Podhorec; Borivoj Vojtesek; Katerina Kankova; Roman Hrstka
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

2.  Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus.

Authors:  Jing Ding; Cong Li; Jie Tang; Cheng Yi; Ji-Yan Liu; Meng Qiu
Journal:  Pathol Oncol Res       Date:  2016-05-02       Impact factor: 3.201

3.  Colon cancer-associated transcript-1 enhances glucose metabolism and colon cancer cell activity in a high-glucose environment in vitro and in vivo.

Authors:  Ge Cui; Yuxuan Huang; Wenming Feng; Yunliang Yao; Hongchang Zhou; Xining Li; Hui Gong; Jun Liu; Yifan Luo; Yandi Sun; Mengya Zhang; Yan Luo; Ting Zhang
Journal:  J Gastrointest Oncol       Date:  2020-12

4.  Characteristics and prognosis of Japanese colorectal cancer patients: The BioBank Japan Project.

Authors:  Akiko Tamakoshi; Koshi Nakamura; Shigekazu Ukawa; Emiko Okada; Makoto Hirata; Akiko Nagai; Koichi Matsuda; Yoichiro Kamatani; Kaori Muto; Yutaka Kiyohara; Zentaro Yamagata; Toshiharu Ninomiya; Michiaki Kubo; Yusuke Nakamura
Journal:  J Epidemiol       Date:  2017-02-15       Impact factor: 3.211

5.  Four targeted genes for predicting the prognosis of colorectal cancer: A bioinformatics analysis case.

Authors:  Qinglai Bian; Jiaxu Chen; Wenqi Qiu; Chenxi Peng; Meifang Song; Xuebin Sun; Yueyun Liu; Fengmin Ding; Jianbei Chen; Liqing Zhang
Journal:  Oncol Lett       Date:  2019-09-13       Impact factor: 2.967

6.  Influence and mechanism of miR-99a suppressing development of colorectal cancer (CRC) with diabetes mellitus (DM).

Authors:  Peixuan Zhu; Jiahao Liu; Meijuan Lu; Gongfa Wu; Xutao Lin; Longmei Cai; Xiaona Zhang
Journal:  Onco Targets Ther       Date:  2019-11-27       Impact factor: 4.147

7.  Mixture cure model for estimating short-term and long-term colorectal cancer survival.

Authors:  Farzaneh Amanpour; Setareh Akbari; Mehdi Azizmohammad Looha; Mohammad Abdehagh; Mohamad Amin Pourhoseingholi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.